Ardelyx (ARDX) Total Non-Current Liabilities (2013 - 2026)

Ardelyx's (ARDX) quarterly Total Non-Current Liabilities came in at $330.0 million in Q1 2026, up 38.67% YoY from $238.0 million in Q1 2025, and up 6.88% on a QoQ basis from $308.8 million in Q4 2025.

Ardelyx (ARDX) Total Non-Current Liabilities (2013 - 2026) Analysis & Trends

Ardelyx (ARDX) has 14 years of Total Non-Current Liabilities data on file, last reported at $330.0 million in Q1 2026.

  • Quarterly Total Non-Current Liabilities rose 38.67% year-over-year to $330.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $330.0 million (up 38.67% YoY) and the FY2025 annual result came in at $308.8 million, up 30.32% from the prior year.
  • Total Non-Current Liabilities grew to $330.0 million in Q1 2026, from $308.8 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $330.0 million in Q1 2026 to a low of $67.4 million in Q3 2022.
  • A 5-year average of $176.5 million and a median of $171.5 million in 2024 frame the typical range for Total Non-Current Liabilities.
  • Annual changes were most pronounced in 2023 — Total Non-Current Liabilities grew 8.52% — and 2024, when it surged 131.65%.
  • Tracing ARDX's Total Non-Current Liabilities over 5 years: stood at $80.5 million in 2022, then jumped by 37.4% to $110.6 million in 2023, then soared by 114.26% to $236.9 million in 2024, then soared by 30.32% to $308.8 million in 2025, then climbed by 6.88% to $330.0 million in 2026.
  • The last three Total Non-Current Liabilities figures came in at $330.0 million (Q1 2026), $308.8 million (Q4 2025), and $303.3 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 5.92 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 7.74 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 40.00 Mn
4 Revolution Medicines 43.64 Bn 43.64 Bn - 1.53 Bn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 1.88 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - 9.32 Bn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 4.20 Bn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 1.17 Bn
10 Ardelyx 1.01 Bn 729.71 Mn 115.12 Mn 400.56 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 400.56 Mn
Mar 31, 2026 330.02 Mn
Dec 31, 2025 308.78 Mn
Sep 30, 2025 303.26 Mn
Jun 30, 2025 299.48 Mn
Mar 31, 2025 238.00 Mn
Dec 31, 2024 236.94 Mn
Sep 30, 2024 185.19 Mn
Jun 30, 2024 173.39 Mn
Mar 31, 2024 169.61 Mn
Dec 31, 2023 110.58 Mn
Sep 30, 2023 98.05 Mn
Jun 30, 2023 74.85 Mn
Mar 31, 2023 79.38 Mn
Dec 31, 2022 80.48 Mn
Sep 30, 2022 67.39 Mn
Jun 30, 2022 68.98 Mn
Dec 31, 2021 67.30 Mn
Dec 31, 2020 74.07 Mn
Sep 30, 2020 65.96 Mn